TU Ilmenau Humbold Bau

Projektsuche


€

0 Projekte gefunden.


Nach den folgenden Parametern kann sortiert werden:

Titel
Hochschule
Fakultät/Einrichtung
Drittmittelgeber
Beginn Ende
Gesamtmittel
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature
UKJ
Medizinische Fakultät
Universitätsklinikum Heidelberg
2024 - 2031
Kategorie 10.000,00 - 99.999,00 €
Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL)
UKJ
Medizinische Fakultät
EU
2024 - 2028
1.714.516,25 €
Anwendung von PEEK-Stäben zur Stabilisierung zirkumferenter lumbaler Spondylodesen
UKJ
Medizinische Fakultät
Deutsche Wirbelsäulenstiftung
2018 - 2020
20.000,00 €
A Phase 1 Clinical Trial to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of TERN-701in Participants with Chronic Myeloid Leukemia
UKJ
Medizinische Fakultät
ICON Clinical Research Limited
2024 - 2025
Kategorie 10.000,00 - 99.999,00 €
A Phase 2, adaptive, randomized, open-label, assessorblinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)
UKJ
Medizinische Fakultät
Novartis Pharma GmbH
2024 - 2029
Kategorie 100.000,00 - 499.999,00 €
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study
UKJ
Medizinische Fakultät
Insmed Incorporated
2024 - 2025
Kategorie 10.000,00 - 99.999,00 €
A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Generalized Myasthenia Gravis (KYSA-6)
UKJ
Medizinische Fakultät
Kyverna Therapeutics, Inc.
2024 - 2026
Kategorie 10.000,00 - 99.999,00 €
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
UKJ
Medizinische Fakultät
Incyte Corporation
2024 - 2028
Kategorie 100.000,00 - 499.999,00 €
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) PlusPembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatmentof Participants With Renal Cell Carcinoma
UKJ
Medizinische Fakultät
MSD SHARP & DOHME GmbH
2024 - 2030
Kategorie 100.000,00 - 499.999,00 €
A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR MONOTHERAPY IN SUBJECTS WITH JAK INHIBITOR-NAÏVE MYELOFIBROSIS AND MODERATE THROMBOCYTOPENIA
UKJ
Medizinische Fakultät
Karyopharm Therapeutics Inc.
2024 - 2028
Kategorie 10.000,00 - 99.999,00 €
Projektsuche | Impressum | FAQ